Cyclo Therapeutics, Inc. (CYTH)

USD 0.63

(-4.58%)

Market Cap (In USD)

18.11 Million

Revenue (In USD)

1.07 Million

Net Income (In USD)

-20.05 Million

Avg. Volume

77.2 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.57-2.12
PE
-
EPS
-
Beta Value
-0.381
ISIN
US23254X2018
CUSIP
550241103
CIK
922247
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. N. Scott Fine
Employee Count
-
Website
https://www.cyclotherapeutics.com
Ipo Date
2000-05-03
Details
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.